Clinical trials are due to begin in the UK this year, to see if the MDMA drug, also known as ecstasy, effectively treat people suffering from PTSD.
Studies have already taken place in the US, which could see approval of the treatment in early 2023.
MDMA increases the release of serotonin hormone in the brain, which in turn increases well-being and feelings of happiness.
- MDMA-assisted therapy for veterans with PTSD faces funding shortfall
- 'Crackers about mental health': Fundraising veteran dresses up for 70th marathon
- Kabul airlift personnel 'face consequences in their mental health', Defence Secretary says
Researchers remain cautious, despite promising early results in the US.
Professor Allan Young, Head of School, Academic Psychiatry, spoke to Forces News to explain how the drug works in combination with therapy and how optimistic the public should be.
More funding is still needed to ensure the clinical trials go ahead this year - the charity Supporting Wounded Veterans is working to raise the shortfall.